A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancerPARK, Y. H; KIM, B.-S; RYOO, B.-Y et al.British journal of cancer. 2006, Vol 94, Num 7, pp 959-963, issn 0007-0920, 5 p.Article

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphomaLEE, J; SUH, C; KANG, H. J et al.Annals of oncology. 2008, Vol 19, Num 12, pp 2079-2083, issn 0923-7534, 5 p.Article

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinumYOON, D. H; RYU, M.-H; PARK, Y. S et al.British journal of cancer. 2012, Vol 106, Num 6, pp 1039-1044, issn 0007-0920, 6 p.Article

A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerLEE, J.-L; KANG, Y.-K; RYU, M.-H et al.British journal of cancer. 2008, Vol 99, Num 4, pp 584-590, issn 0007-0920, 7 p.Article

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type : a national survey of the Korean Cancer Study GroupKIM, T. M; LEE, S.-Y; KIM, J. S et al.Annals of oncology. 2008, Vol 19, Num 8, pp 1477-1484, issn 0923-7534, 8 p.Article

Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumorsYOO, C; RYU, M.-H; NA, Y. S et al.Annals of oncology. 2014, Vol 25, Num 11, pp 2272-2277, issn 0923-7534, 6 p.Article

Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junctionRYOO, B.-Y; KANG, Y.-K; SHIM, Y. M et al.American journal of clinical oncology. 1999, Vol 22, Num 3, pp 253-257, issn 0277-3732Article

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinibKANG, Y.-K; YOO, C; RYU, M.-H et al.British journal of cancer. 2013, Vol 109, Num 9, pp 2309-2315, issn 0007-0920, 7 p.Article

A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancerKANG, Y.-K; RYOO, B.-Y; KIM, T. Y et al.Cancer chemotherapy and pharmacology. 1999, Vol 44, Num 6, pp 518-521, issn 0344-5704Article

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancerPARK, Y. H; RYOO, B-Y; CHOI, S-J et al.British journal of cancer. 2004, Vol 90, Num 7, pp 1329-1333, issn 0007-0920, 5 p.Article

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer : results of a multicenter early phase II studyLEE, D. H; KIM, S.-W; KIM, N. K et al.Annals of oncology. 2008, Vol 19, Num 1, pp 123-127, issn 0923-7534, 5 p.Article

Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumoursRYU, M. H; KANG, Y. K; LEE, J. L et al.Histopathology. 2007, Vol 51, Num 3, pp 379-389, issn 0309-0167, 11 p.Article

High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma : a retrospective comparison with non-transplantation casesKIM, H. J; BANG, S. M; OH, S. Y et al.KIM, H. J; Bone marrow transplantation (Basingstoke). 2006, Vol 37, Num 9, pp 819-824, issn 0268-3369, 6 p.Article